Doctors Would Likely Get Chunk Of 20% Difference In List Price Between Biosimilars

By John Wilkerson
July 28, 2017 at 2:42 PM
The list price of the second Remicade biosimilar, Renflexis, is 20 percent lower than that of the first Remicade biosimilar, and doctors who prescribe Renflexis would likely get a good chunk of that 20 percent difference because both biosimilars are in the same billing code, sources say. If providers widely adopt Renflexis based on the bigger profits they could make, the Medicare reimbursement for both biosimilars would drop for the rheumatoid arthritis treatments. CMS decided to group biosimilars in common...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on the coming Democrat-controlled House of Representatives, drug pricing reforms, Medicaid policy, FDA news and much more.